Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 5/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 2/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 2/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | ACHE | P22303 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.81 |
| ▸ | PRKCA | P17252 | 1/20 | 0.81 |
| ▸ | BACE1 | P56817 | 1/20 | 0.81 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sophoraflavanone B SCHEMBL29396586 | 1.00 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL1171435 | 1.00 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL14304885 | 1.00 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL1931652 | 0.99 | ESR1 (0.98) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL30138890 | 0.93 | ESR1 (0.86) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL12961707 | 0.91 | ESR1 (0.84) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Glabranin SCHEMBL320136 | 0.91 | CYP3A4 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Glabranin SCHEMBL320135 | 0.91 | CYP3A4 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone A SCHEMBL29624617 | 0.91 | ABCG2 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone A SCHEMBL141996 | 0.91 | ABCG2 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622943-B2 | Composition for relieving woman menopausal symptom comprising a mixed extract of hop and citrus peel and method for treating or alleviating menopausal symptom using the same | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2026-05-12 | — | — | US | claimed |
| US-12594313-B2 | Composition for alleviating cardiovascular disease or osteoporosis, comprising mixed extract of hop and cynanchum wilfordii as active ingredient, and method for treating or alleviating cardiovascular disease or osteoporosis using same | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2026-04-07 | — | — | US | claimed |
| US-12485105-B2 | Composition for suppressing obesity | DAICEL CORPORATION (JP) | 2025-12-02 | — | — | US | claimed |
| EP-4623074-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | Epimeron USA, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250270598-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | EPIMERON USA, INC. (US) | 2025-08-28 | — | — | US | claimed |
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4543220-A2 | COMPOSITIONS FOR REDUCING METHANE EMISSIONS, ANIMAL FEEDS COMPRISING THEM AND THEIR USE TO REDUCE METHANE EMISSIONS | Mootral Innovations Limited (GB) | 2025-04-30 | — | — | EP | claimed |
| CN-119899829-A | Yarrowia lipolytica engineering bacterium for producing isopentenyl aromatic compound, construction method and application thereof | 山东大学 | 2025-04-29 | — | — | CN | claimed |
| CN-119730731-A | Composition for reducing methane emissions, animal feed containing same and use thereof for reducing methane emissions | 莫特迩创新有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-1294388-B1 | EXTRACTS FROM SOPHORA SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | SCHWABE WILLMAR GMBH & CO (DE) | 2004-01-07 | — | — | EP | claimed |
| WO-2003094910-A1 | USE OF 8-PRENYLFLAVANONES FOR ANTI-ANGIOGENESIS THERAPY AND FOR FIBRINOLYTIC THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-20 | — | — | WO | claimed |
| EP-1360959-A1 | Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy | Schering Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | claimed |
| US-20030180394-A1 | Extracts from sophora species, method for producing the same and their use | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2003-09-25 | — | — | US | claimed |
| EP-1333805-A2 | COSMETIC METHOD OF TREATING SKIN | UNILEVER PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| WO-2003014287-A1 | HOPS EXTRACTS, METHOD FOR THE PRODUCTION AND USE | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2003-02-20 | — | — | WO | claimed |
| WO-2002085393-A1 | HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES | BERKEM (FR) | 2002-10-31 | — | — | WO | claimed |
| US-20020110579-A1 | Use of prenylated flavones | LIPTON, DIVISION OF CONOPCO, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002039960-A2 | COSMETIC METHOD OF TREATING SKIN | UNILEVER PLC (GB) | 2002-05-23 | — | — | WO | claimed |
| EP-1190630-A1 | Use of prenylated flavones | UNILEVER N.V. (NL) | 2002-03-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622943-B2 | Composition for relieving woman menopausal symptom comprising a mixed extract of hop and citrus peel and method for treating or alleviating menopausal symptom using the same | PGR, FSHR, PTH1R | ESR1 12/4885ESR2 64/4885ABCG2 3986/4885 |
| US-12594313-B2 | Composition for alleviating cardiovascular disease or osteoporosis, comprising mixed extract of hop and cynanchum wilfordii as active ingredient, and method for treating or alleviating cardiovascular disease or osteoporosis using same | BMP2, COL2A1, COL1A1 | ESR1 1964/4885ESR2 659/4885ABCG2 3922/4885 |
| US-12485105-B2 | Composition for suppressing obesity | FABP4, SREBF1, GPR119 | ESR1 1123/4885ESR2 561/4885ABCG2 3704/4885 |
| US-20030180394-A1 | Extracts from sophora species, method for producing the same and their use | CYP19A1, SHBG, CYP17A1 | ESR1 10/4885ESR2 17/4885ABCG2 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.